Trial · NCT02301390

INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events

NCT02301390, Not applicable, Terminated, Icahn School of Medicine at Mount Sinai; results first posted 2020-01-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events. Trials, record NCT02301390. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02301390

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events
NCT number: NCT02301390
Status: Terminated
Phases: Not applicable
Enrollment: 53 participants, actual
Lead sponsor: Icahn School of Medicine at Mount Sinai
Conditions: Ventricular Tachycardia
Interventions: Amiodarone, Catheter Ablation
First posted: 2014-11-25
Last updated: 2020-01-27
Results first posted: 2020-01-27

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest	at 24 months	Number of participants who had no occurrences of all-cause mortality, sustained ventricular tachycardia (VT) and cardiac arrest at 24 months
Secondary	Number of Participant Who Died	up to 24 months	Number of subjects that die within 30 days or die by 24 months.
Secondary	Ventricular Arrhythmic Events	at 24 months	Total number of ventricular arrhythmic events, compared between the 2 treatment arms.
Secondary	Change in LV Ejection Fraction	baseline and 24 months	Change in left ventricle (LV) ejection fraction between paired measurements recorded at 24 months as compared to baseline

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest	at 24 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participant Who Died	up to 24 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Ventricular Arrhythmic Events	at 24 months		events	NUMBER
SECONDARY	Change in LV Ejection Fraction	baseline and 24 months	Data for only those who had two time points LV ejection fraction data	percent	MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest	Amiodarone Only		16		Participants
Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest	Amiodarone + Catheter Ablation		21		Participants
Number of Participant Who Died	Amiodarone Only	within 30 days	0		Participants
Number of Participant Who Died	Amiodarone + Catheter Ablation	within 30 days	0		Participants
Number of Participant Who Died	Amiodarone Only	24 months	2		Participants
Number of Participant Who Died	Amiodarone + Catheter Ablation	24 months	2		Participants
Ventricular Arrhythmic Events	Amiodarone Only		15		events
Ventricular Arrhythmic Events	Amiodarone + Catheter Ablation		5		events
Change in LV Ejection Fraction	Amiodarone Only		1.85	Standard Deviation 6.32	percent
Change in LV Ejection Fraction	Amiodarone + Catheter Ablation		8	Standard Deviation .31	percent

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Amiodarone Only	27
Overall Study	STARTED	Amiodarone + Catheter Ablation	26
Overall Study	COMPLETED	Amiodarone Only	17
Overall Study	COMPLETED	Amiodarone + Catheter Ablation	13
Overall Study	NOT COMPLETED	Amiodarone Only	10
Overall Study	NOT COMPLETED	Amiodarone + Catheter Ablation	13

Source ClinicalTrials.gov

Adverse events42

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Bradycardia	Cardiac disorders	Amiodarone Only	2	27
other	Bradycardia	Cardiac disorders	Amiodarone + Catheter Ablation	3	26
other	Hypothyroidism	Endocrine disorders	Amiodarone Only	0	27
other	Hypothyroidism	Endocrine disorders	Amiodarone + Catheter Ablation	1	26
other	Transient AV block while crossing the Aortic Valve	Cardiac disorders	Amiodarone Only	0	27
other	Transient AV block while crossing the Aortic Valve	Cardiac disorders	Amiodarone + Catheter Ablation	1	26
other	Chronic progressive gingivitis	General disorders	Amiodarone Only	0	27
other	Chronic progressive gingivitis	General disorders	Amiodarone + Catheter Ablation	1	26
other	right foot injury	Musculoskeletal and connective tissue disorders	Amiodarone Only	0	27
other	right foot injury	Musculoskeletal and connective tissue disorders	Amiodarone + Catheter Ablation	1	26

1 to 10 of 42Source ClinicalTrials.gov

See all 42 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Amiodarone Only	2	27
Total, all-cause mortality	Amiodarone + Catheter Ablation	2	26
Total, other adverse events	Amiodarone Only	4	27
Total, other adverse events	Amiodarone + Catheter Ablation	6	26
Total, serious adverse events	Amiodarone Only	11	27
Total, serious adverse events	Amiodarone + Catheter Ablation	8	26

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Amiodarone Only vs Amiodarone + Catheter Ablation: Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest	Trial comparisons
Amiodarone Only vs Amiodarone + Catheter Ablation: deaths from any cause	Trial comparisons
Amiodarone Only vs Amiodarone + Catheter Ablation: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02301390

GET https://conductscience.org/api/trials/v1/NCT02301390/events?page=2

API reference For AI assistants